Glipizide extended-release capsules

This product is a sulfonylurea antidiabetic drug, which is effective for most patients with type 2 diabetes. It can reduce fasting and postprandial blood sugar and reduce glycosylated hemoglobin (HbA1c) by 1%-2%. The main function of this type of drug is to stimulate the pancreatic beta cells to secrete insulin, but the prerequisite is that the pancreatic beta cells still have a certain function of synthesizing and secreting insulin. Its mechanism is to specifically bind to the sulfonylurea receptors on the beta cell membrane, thereby closing the K channel, causing changes in membrane potential, opening the Ca2 channel, and increasing the intracellular Ca2, which promotes insulin secretion. In addition, there are extra-pancreatic effects, including improving the insulin resistance of peripheral tissues (such as liver, muscle, and fat).

The main ingredient is glipizide. Its chemical name is 5-methyl-N-[2-[4-[[[(cyclohexylamino)carboxyl]sulfonyl]phenyl]ethyl]-pyrazinecarboxamide. Its molecular formula is C21H27N5O4S21; its molecular weight is 445.54

This product is a hard capsule containing white spherical pellets.

Blood sugar lowering medication.

Oral administration, dosage varies from person to person, generally recommended starting dose is 5 mg/day, once a day, taken at breakfast. The dosage can be adjusted later according to blood sugar levels.

1. The most common symptoms are gastrointestinal symptoms (such as nausea, upper abdominal distension), headache, etc., which can be relieved by reducing the dose. 2. Some patients may experience skin allergies. 3. Hypoglycemia is occasionally seen, especially in the elderly and weak, those who are overactive, those who eat irregularly, drink alcohol, or have liver damage. There are also occasional reports of reversible changes in the hematopoietic system.

1. Patients allergic to sulfonamides. 2. Patients with type 1 diabetes who have been diagnosed. 3. Patients with type 2 diabetes accompanied by stressful conditions such as ketoacidosis, coma, severe burns, infection, trauma, and major surgery. 4. Patients with impaired liver and kidney function. 5. Patients with leukopenia.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: 1. Animal experiments and clinical observations have shown that sulfonylurea hypoglycemic drugs can cause stillbirth and fetal malformation, so pregnant women are prohibited from using them. 2. This type of animal can be excreted through breast milk, so nursing mothers should not use it to avoid hypoglycemia in infants. Precautions for the elderly: Not yet clear.

1. This drug can increase its hypoglycemic effect when used in combination with coumarins, monoamine oxidase inhibitors, phenylbutazone, sulfonamides, chloramphenicol, cyclophosphamide, probenecid, and salicylic acid drugs. 2. When used in combination with adrenaline, adrenocortical hormones, oral contraceptives, and thiazide diuretics, its hypoglycemic effect can be reduced. 3. Be cautious when using it in combination with beta-blockers. 4. Gastrointestinal diseases that shorten the retention time of this product in the gastrointestinal tract can affect the pharmacokinetics and efficacy of this product.

Keep away from light and sealed in a dry place. Valid for 2 years.

10mg

24 months

Hangzhou Conba Pharmaceutical Co., Ltd.

• Founded in:

  2000-03-27

• Address:

  No. 568, Binkang Road, Changhe Street, Binjiang District, Hangzhou City, Zhejiang Province

• Tax NO.:

  91330108716159914E

• Registered Funds:

  380 million yuan

• Website:

  Log in to view

• Email:

  Log in to view